Dr Reddy's Labs to Release Q3FY26 Results on January 21 with Earnings Call

Dr Reddy's Laboratories has announced that its board of directors will convene on January 21, 2026 to consider and approve the company's Q3FY26 financial results. The pharmaceutical major will release results for the quarter and nine months ended December 31, 2025, following standard corporate governance practices.

Board Meeting and Results Release

The company has formally notified stakeholders about the upcoming board meeting through a regulatory filing under Regulation 30. The results will be announced after the board meeting concludes, with distribution across multiple channels including stock exchanges, media, and the company website.

Event Details:	Information
Results Release Date:	January 21, 2026
Quarter Period:	Q3FY26 (ended December 31, 2025)
Distribution Channels:	Stock Exchange, Media, Company Website
Regulatory Filing:	Under Regulation 30

Earnings Call Schedule

Following the results announcement, Dr Reddy's Laboratories management will host an earnings call to discuss the company's financial performance. The call is scheduled for January 21, 2026 at 19:30 PM IST (9:00 AM ET).

Earnings Call Details:	Information
Date & Time:	January 21, 2026 at 19:30 PM IST
International Time:	9:00 AM ET
Format:	Company-hosted webinar
Registration:	Pre-registration required via Zoom link

Stakeholder Access

The company will make comprehensive information available to stakeholders through multiple formats. A press meet presentation will be accessible on the company website, while both audio recordings and transcripts of the earnings call will be made available post-event on the company website and filed with stock exchanges.

As one of India's prominent pharmaceutical companies, Dr Reddy's Laboratories' quarterly results are closely monitored by investors, analysts, and industry observers for insights into operational performance and financial health during the reporting period.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.81%	-2.86%	-9.47%	-7.98%	-11.15%	+13.88%

Dr Reddys Laboratories has received regulatory attention from the US Food and Drug Administration (USFDA) following an inspection at one of its key manufacturing facilities. The pharmaceutical company announced that the USFDA has completed its Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI) review at the company's Srikakulam plant.

USFDA Inspection Outcome

Following the comprehensive review, the regulatory authority has issued a Form 483 to the company. This regulatory document identifies five specific concerns that were observed during the inspection process at the Srikakulam facility.

Inspection Details	Information
Facility Location	Srikakulam Plant
Inspection Type	GMP and PAI Review
Regulatory Document	Form 483
Number of Concerns	5

Understanding Form 483

Form 483 represents the USFDA's formal communication to pharmaceutical companies regarding observations made during facility inspections. When issued, it indicates that inspectors have identified conditions or practices that may constitute violations of food and drug laws and regulations.

Regulatory Implications

The issuance of Form 483 requires the company to provide a written response addressing each concern raised by the USFDA. Companies typically have 15 working days to respond with corrective actions and timelines for implementation. The pharmaceutical manufacturer will need to demonstrate how it plans to resolve the identified issues to maintain compliance with US regulatory standards.

This development at the Srikakulam facility represents a regulatory checkpoint that Dr Reddys Laboratories must navigate as part of its ongoing operations in the US pharmaceutical market. The company will need to address the five regulatory concerns cited by the USFDA to ensure continued compliance and smooth operations at the facility.